-
Something wrong with this record ?
Oncogenic microRNA-155 and its target PU.1: an integrative gene expression study in six of the most prevalent lymphomas
H. Huskova, K. Korecka, J. Karban, J. Vargova, K. Vargova, N. Dusilkova, M. Trneny, T. Stopka,
Language English Country Japan
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
ProQuest Central
from 2001-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2011-01-01 to 1 year ago
Nursing & Allied Health Database (ProQuest)
from 2001-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2001-01-01 to 1 year ago
- MeSH
- ADP-ribosyl Cyclase 1 metabolism MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Lymphoma metabolism mortality MeSH
- MicroRNAs biosynthesis MeSH
- Biomarkers, Tumor biosynthesis MeSH
- Prevalence MeSH
- ZAP-70 Protein-Tyrosine Kinase metabolism MeSH
- Proto-Oncogene Proteins biosynthesis MeSH
- Gene Expression Regulation, Neoplastic * MeSH
- RNA, Neoplasm biosynthesis MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Trans-Activators biosynthesis MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
The transcription factor PU.1 and its inhibitory microRNA-155 (miR-155) are important regulators of B-cell differentiation. PU.1 downregulation coupled with oncogenic miR-155 upregulation has been reported in lymphoid malignancies; however, these data have not been studied across different subtypes in relation to clinical outcomes. We studied expression of miR-155 and PU.1 in the six most prevalent human B-cell lymphomas (n = 131) including aggressive (DLBCL, HL, MCL) and indolent (B-CLL/SLL, MZL, FL) types. Levels of miR-155 and PU.1 inversely correlated in DLBCL, B-CLL/SLL, and FL tumor tissues. In HL tissues, an exceptionally high level of miR-155 was found in patients with unfavorable responses to first-line therapy and those who had shorter survival times. PU.1 downregulation was noted in B-CLL/SLL samples positive for the adverse prognostic markers CD38 and ZAP-70. Upregulation of miR-155 and downregulation of PU.1 expression are integral aspects of lymphoma biology that could mark aggressive behavior of some, but not all, lymphoma types.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16028311
- 003
- CZ-PrNML
- 005
- 20161024105223.0
- 007
- ta
- 008
- 161005s2015 ja f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s12185-015-1847-4 $2 doi
- 024 7_
- $a 10.1007/s12185-015-1847-4 $2 doi
- 035 __
- $a (PubMed)26261072
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ja
- 100 1_
- $a Huskova, Hana $u Institute of Pathological Physiology, 1st Medical Faculty, Charles University in Prague, U Nemocnice 5, 128 53, Prague, Czech Republic.
- 245 10
- $a Oncogenic microRNA-155 and its target PU.1: an integrative gene expression study in six of the most prevalent lymphomas / $c H. Huskova, K. Korecka, J. Karban, J. Vargova, K. Vargova, N. Dusilkova, M. Trneny, T. Stopka,
- 520 9_
- $a The transcription factor PU.1 and its inhibitory microRNA-155 (miR-155) are important regulators of B-cell differentiation. PU.1 downregulation coupled with oncogenic miR-155 upregulation has been reported in lymphoid malignancies; however, these data have not been studied across different subtypes in relation to clinical outcomes. We studied expression of miR-155 and PU.1 in the six most prevalent human B-cell lymphomas (n = 131) including aggressive (DLBCL, HL, MCL) and indolent (B-CLL/SLL, MZL, FL) types. Levels of miR-155 and PU.1 inversely correlated in DLBCL, B-CLL/SLL, and FL tumor tissues. In HL tissues, an exceptionally high level of miR-155 was found in patients with unfavorable responses to first-line therapy and those who had shorter survival times. PU.1 downregulation was noted in B-CLL/SLL samples positive for the adverse prognostic markers CD38 and ZAP-70. Upregulation of miR-155 and downregulation of PU.1 expression are integral aspects of lymphoma biology that could mark aggressive behavior of some, but not all, lymphoma types.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a antigeny CD38 $x metabolismus $7 D051997
- 650 _2
- $a nádorové biomarkery $x biosyntéza $7 D014408
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a regulace genové exprese u nádorů $7 D015972
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lymfom $x metabolismus $x mortalita $7 D008223
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mikro RNA $x biosyntéza $7 D035683
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a prevalence $7 D015995
- 650 _2
- $a protoonkogenní proteiny $x biosyntéza $7 D011518
- 650 _2
- $a RNA nádorová $x biosyntéza $7 D012334
- 650 _2
- $a trans-aktivátory $x biosyntéza $7 D015534
- 650 _2
- $a protein-tyrosinkináza ZAP-70 $x metabolismus $7 D051746
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Korecka, Katarina $u 1st Medical Department - Hematology, General Faculty Hospital, U Nemocnice 2, 128 08, Prague, Czech Republic.
- 700 1_
- $a Karban, Josef $u 1st Medical Department - Hematology, General Faculty Hospital, U Nemocnice 2, 128 08, Prague, Czech Republic.
- 700 1_
- $a Vargova, Jarmila $u Institute of Pathological Physiology, 1st Medical Faculty, Charles University in Prague, U Nemocnice 5, 128 53, Prague, Czech Republic.
- 700 1_
- $a Vargova, Karina $u Institute of Pathological Physiology, 1st Medical Faculty, Charles University in Prague, U Nemocnice 5, 128 53, Prague, Czech Republic.
- 700 1_
- $a Dusilkova, Nina $u Institute of Pathological Physiology, 1st Medical Faculty, Charles University in Prague, U Nemocnice 5, 128 53, Prague, Czech Republic.
- 700 1_
- $a Trneny, Marek $u 1st Medical Department - Hematology, General Faculty Hospital, U Nemocnice 2, 128 08, Prague, Czech Republic.
- 700 1_
- $a Stopka, Tomas $u Institute of Pathological Physiology, 1st Medical Faculty, Charles University in Prague, U Nemocnice 5, 128 53, Prague, Czech Republic. tstopka@lf1.cuni.cz. 1st Medical Department - Hematology, General Faculty Hospital, U Nemocnice 2, 128 08, Prague, Czech Republic. tstopka@lf1.cuni.cz.
- 773 0_
- $w MED00002329 $t International journal of hematology $x 1865-3774 $g Roč. 102, č. 4 (2015), s. 441-50
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26261072 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20161005 $b ABA008
- 991 __
- $a 20161024105635 $b ABA008
- 999 __
- $a ok $b bmc $g 1166625 $s 952941
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 102 $c 4 $d 441-50 $e 20150811 $i 1865-3774 $m International journal of hematology $n Int J Hematol $x MED00002329
- LZP __
- $a Pubmed-20161005
